Bimekizumab is a Monoclonal Antibody owned by UCB, and is involved in 40 clinical trials, of which 33 were completed, 6 are ongoing, and 1 is planned.
Bimekizumab acts by inhibiting interleukin- 17A and L-17F. Interleukin- 17 is an cytokine. IL-17 expression is detectable in biopsies from lesional psoriatic skin. IL-17 has also been implicated in inflammatory skin diseases. IL-17 enhances the neutrophil chemotaxis.
The revenue for Bimekizumab is expected to reach a total of $36bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Bimekizumab NPV Report.
Bimekizumab is originated and owned by UCB.
Bimekizumab (Bimzelx) is a humanised IgG1monoclonal antibody produced in a genetically engineered Chinese hamster ovary (CHO) cell line by recombinant DNA technology. It is formulated as solution for injection in pre-filled syringe and pre-filled pen for subcutaneous route of administration. Bimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Bimzelx is indicated for the treatment of plaque psoriasis, generalized pustular psoriasis and psoriatic erythroderma in patients who are not sufficiently responding to existing treatments
Bimekizumab (UCB-4940) is under development for the treatment of immunological diseases including non-radiographic axial spondyloarthritis, ankylosing spondylitis, plaque psoriasis, hidradenitis suppurativa and psoriatic arthritis. The drug candidate is a new biological entity (Nbe). It is administered intravenously and as subcutaneous solution. The therapeutic candidate is a humanized monoclonal antibody against IL17A and IL17F. It was also under development for the treatment of non-radiographic axial spondyloarthritis, ankylosing spondylitis, rheumatoid arthritis and moderate to severe active ulcerative colitis (intravenous).
UCB is a biopharmaceutical company that is engaged in the discovery and development of novel medicines and solutions for the treatment of various severe diseases. It strives to develop products for the treatment of neurology and immunology related conditions. The company’s marketed products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn’s disease, psoriatic arthritis, non-radiographic axial spondyloarthritis and rheumatoid arthritis; Neupro for Parkinson’s disease and restless legs syndrome; Evenity for osteoporosis, and Vimpat, Keppra and Briviact for epilepsy. The company operates through subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Brussels-Capital Region, Belgium.
The company reported revenues of (Euro) EUR5,777 million for the fiscal year ended December 2021 (FY2021), an increase of 8% over FY2020. In FY2021, the company’s operating margin was 22.2%, compared to an operating margin of 18.2% in FY2020. In FY2021, the company recorded a net margin of 18.3%, compared to a net margin of 13.7% in FY2020.
Quick View – Bimekizumab
|Highest Development Stage|